1
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Millikan RC, Newman B, Tse CK, Moorman PG,
Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT,
et al: Epidemiology of basal-like breast cancer. Breast Cancer Res
Treat. 109:123–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Skor MN, Wonder EL, Kocherginsky M, Goyal
A, Hall BA, Cai Y and Conzen SD: Glucocorticoid receptor antagonism
as a novel therapy for triple-negative breast cancer. Clin Cancer
Res. 19:6163–6172. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lonergan PE and Tindall DJ: Androgen
receptor signaling in prostate cancer development and progression.
J Carcinogenesis. 10:202011. View Article : Google Scholar
|
5
|
Mrklic I, Pogorelic Z, Capkun V and Tomić
S: Expression of androgen receptors in triple negative breast
carcinomas. Acta Histochem. 115:344–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Vera-Badillo FE, Templeton AJ, de Gouveia
P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF,
Ocana A and Amir E: Androgen receptor expression and outcomes in
early breast cancer: A systematic review and meta-analysis. J Natl
Cancer Inst. 106:djt3192014. View Article : Google Scholar : PubMed/NCBI
|
7
|
He J, Peng R, Yuan Z, Wang S, Peng J, Lin
G, Jiang X and Qin T: Prognostic value of androgen receptor
expression in operable triple-negative breast cancer: A
retrospective analysis based on a tissue microarray. Med Oncol.
29:406–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
Gerratana L, Basile D, Buono G, De Placido
S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del
Mastro L, et al: Androgen receptor in triple negative breast
cancer: A potential target for the targetless subtype. Cancer Treat
Rev. 68:102–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
9
|
Satterwhite E, Sonoki T, Willis TG, Harder
L, Nowak R, Arriola EL, Liu H, Price HP, Gesk S, Steinemann D, et
al: The BCL11 gene family: Involvement of BCL11A in lymphoid
malignancies. Blood. 98:3413–3420. 2001. View Article : Google Scholar : PubMed/NCBI
|
10
|
Saiki Y, Yamazaki Y, Yoshida M, Katoh O
and Nakamura T: Human EVI9, a homologue of the mouse myeloid
leukemia gene, is expressed in the hematopoietic progenitors and
down-regulated during myeloid differentiation of HL60 cells.
Genomics. 70:387–391. 2000. View Article : Google Scholar : PubMed/NCBI
|
11
|
Jin C, Yu W, Lou X, Zhou F, Han X, Zhao N
and Lin B: UCHL1 is a putative tumor suppressor in ovarian cancer
cells and contributes to cisplatin resistance. J Cancer. 4:662–670.
2013. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Boelens MC, Kok K, van der Vlies P, van
der Vries G, Sietsma H, Timens W, Postma DS, Groen HJ and van den
Berg A: Genomic aberrations in squamous cell lung carcinoma related
to lymph node or distant metastasis. Lung Cancer. 66:372–378. 2009.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Podgornik H, Pretnar J, Skopec B,
Andoljšek D and Černelč P: Concurrent rearrangements of BCL2, BCL3,
and BCL11A genes in atypical chronic lymphocytic leukemia.
Hematology. 19:45–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kapatai G and Murray P: Contribution of
the Epstein Barr virus to the molecular pathogenesis of Hodgkin
lymphoma. J Clin Pathol. 60:1342–1349. 2007. View Article : Google Scholar : PubMed/NCBI
|
15
|
Chetaille B, Bertucci F, Finetti P,
Esterni B, Stamatoullas A, Picquenot JM, Copin MC, Morschhauser F,
Casasnovas O, Petrella T, et al: Molecular profiling of classical
Hodgkin lymphoma tissues uncovers variations in the tumor
microenvironment and correlations with EBV infection and outcome.
Blood. 113:2765–3775. 2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Agueli C, Cammarata G, Salemi D, Dagnino
L, Nicoletti R, La Rosa M, Messana F, Marfia A, Bica MG, Coniglio
ML, et al: 14q32/miRNA clusters loss of heterozygosity in acute
lymphoblastic leukemia is associated with up-regulation of BCL11a.
Am J Hematol. 85:575–578. 2010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Jiang BY, Zhang XC, Su J, Meng W, Yang XN,
Yang JJ, Zhou Q, Chen ZY, Chen ZH, Xie Z, et al: BCL11A
overexpression predicts survival and relapse in non-small cell lung
cancer and is modulated by microRNA-30a and gene amplification. Mol
Cancer. 12:612013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Lazarus KA, Hadi F, Zambon E, Bach K,
Santolla MF, Watson JK, Correia LL, Das M, Ugur R, Pensa S, et al:
BCL11A interacts with SOX2 to control the expression of epigenetic
regulators in lung squamous carcinoma. Nat Commun. 9:33272018.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Zhang X, Wang L, Wang Y, Shi S, Zhu H,
Xiao F, Yang J, Yang A and Hao X: Inhibition of FOXQ1 induces
apoptosis and suppresses proliferation in prostate cancer cells by
controlling BCL11A/MDM2 expression. Oncol Rep. 36:2349–2356. 2016.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Kaneda H, Arao T, Tanaka K, Tamura D,
Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y,
et al: FOXQ1 is overexpressed in colorectal cancer and enhances
tumorigenicity and tumor growth. Cancer Res. 70:2053–2063. 2010.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Zhu L, Pan R, Zhou D, Ye G and Tan W:
BCL11A enhances stemness and promotes progression by activating
Wnt/β-catenin signaling in breast cancer. Cancer Manag Res.
11:2997–3007. 2019. View Article : Google Scholar : PubMed/NCBI
|
22
|
He D, Wu H, Ding L and Li Y: Combination
of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6
cells. Eur J Med Res. 19:342014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Gao Y, Wu H, He D, Hu X and Li Y:
Downregulation of BCL11A by siRNA induces apoptosis in B lymphoma
cell lines. Biomed Rep. 1:47–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Yang F, Shen Y, Zhang W, Jin J, Huang D,
Fang H, Ji W, Shi Y, Tang L, Chen W, et al: An androgen receptor
negatively induced long non-coding RNA ARNILA binding to miR-204
promotes the invasion and metastasis of triple-negative breast
cancer. Cell Death Differ. 25:2209–2220. 2018. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zhu A, Li Y, Song W, Xu Y, Yang F, Zhang
W, Yin Y and Guan X: Antiproliferative effect of androgen receptor
inhibition in mesenchymal Stem-like triple-negative breast cancer.
Cell Physiol Biochem. 38:1003–1014. 2016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Zhang W, Luo J, Yang F, Wang Y, Yin Y,
Strom A, Gustafsson JÅ and Guan X: BRCA1 inhibits AR-mediated
proliferation of breast cancer cells through the activation of
SIRT1. Sci Rep. 6:220342016. View Article : Google Scholar : PubMed/NCBI
|
27
|
Ji W, Shi Y, Wang X, He W, Tang L, Tian S,
Jiang H, Shu Y and Guan X: Combined androgen receptor blockade
overcomes the resistance of breast cancer cells to palbociclib. Int
J Biol Sci. 15:522–532. 2019. View Article : Google Scholar : PubMed/NCBI
|
28
|
Sankaran VG, Xu J, Ragoczy T, Ippolito GC,
Walkley CR, Maika SD, Fujiwara Y, Ito M, Groudine M, Bender MA, et
al: Developmental and species-divergent globin switching are driven
by BCL11A. Nature. 460:1093–1097. 2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Lin Y, Zhang Q, Zhang HM, Liu W, Liu CJ,
Li Q and Guo AY: Transcription factor and miRNA co-regulatory
network reveals shared and specific regulators in the development
of B cell and T cell. Sci Rep. 5:152152015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Hayashi N, Manyam GC, Gonzalez-Angulo AM,
Niikura N, Yamauchi H, Nakamura S, Hortobágyi GN, Baggerly KA and
Ueno NT: Reverse-phase protein array for prediction of patients at
low risk of developing bone metastasis from breast cancer.
Oncologist. 19:909–914. 2014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Tsang JC, Yu Y, Burke S, Buettner F, Wang
C, Kolodziejczyk AA, Teichmann SA, Lu L and Liu P: Single-cell
transcriptomic reconstruction reveals cell cycle and multi-lineage
differentiation defects in Bcl11a-deficient hematopoietic stem
cells. Genome Biol. 16:1782015. View Article : Google Scholar : PubMed/NCBI
|
32
|
Wiegreffe C, Simon R, Peschkes K, Kling C,
Strehle M, Cheng J, Srivatsa S, Liu P, Jenkins NA, Copeland NG, et
al: Bcl11a (Ctip1) controls migration of cortical projection
neurons through regulation of Sema3c. Neuron. 87:311–325. 2015.
View Article : Google Scholar : PubMed/NCBI
|